On December 1, 2022, Diffusion Pharmaceuticals Inc announced that it has filed a preliminary proxy statement and stated that it does not endorse the LifeSci Special Opportunities Master Fund Ltd nominees at the 2022 annual meeting of shareholders. In addition, the Company urged the shareholders vote for its board nominees Robert Adams, Robert J. Cobuzzi Jr, Mark T Giles, Jane H Hollingsworth, Diana Lanchoney and Alan Levin, at the annual meeting of shareholders scheduled to be held on December 30, 2022.